Ontology highlight
ABSTRACT: Introduction
Despite the poor prognosis for adults with relapsed or refractory (RR) Philadelphia chromosome (Ph)-negative B cell precursor acute lymphoblastic leukemia (ALL), long-term survival is possible and may even be considered as "cure".Methods
This study used a Delphi panel approach to explore concepts of cure in RR Ph-negative B cell precursor ALL. Ten European experts in this disease area participated in a survey and face-to-face panel meeting.Results
Findings showed that clinicians conceptualize "cure" as a combination of three broad treatment outcomes that vary depending on the treatment stage: complete remission early in treatment (1-3 months) indicates initial success; eradicating cancer cells (minimal residual disease negative status) consolidates the early clinical response; leukemia-free survival is required in the long term.Conclusions
Although such terminology remains contested, clinicians would begin considering "cure" as early as 2 years provided the patient is off therapy, with most considering the term applicable by the third year.Funding
Amgen Inc.
SUBMITTER: Bassan R
PROVIDER: S-EPMC6824362 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
Bassan Renato R Hoelzer Dieter D Thomas Xavier X Montesinos Pau P Pavlu Jiri J McKendrick Jan J Kudlac Amber A Barlev Arie A Barber Beth B Cong Ze Z
Advances in therapy 20190307 4
<h4>Introduction</h4>Despite the poor prognosis for adults with relapsed or refractory (RR) Philadelphia chromosome (Ph)-negative B cell precursor acute lymphoblastic leukemia (ALL), long-term survival is possible and may even be considered as "cure".<h4>Methods</h4>This study used a Delphi panel approach to explore concepts of cure in RR Ph-negative B cell precursor ALL. Ten European experts in this disease area participated in a survey and face-to-face panel meeting.<h4>Results</h4>Findings sh ...[more]